Bright Future Pharmaceutical(Hainan) Co., Ltd.

This product is an angiotensin II receptor antagonist, which can selectively block the binding of angiotensin II to AT1 receptors of tissue cells such as adrenal glands and vascular smooth muscle, inhibit vasoconstriction and aldosterone secretion, and produce a hypotensive effect. The affinity of this product for AT1 receptors is about 20,000 times higher than that for AT2 receptors. This product does not affect the action of bradykinin and ion channel function, nor does it bind to the receptors of other hormones that play an important regulatory role in cardiovascular function. This product has no carcinogenic, teratogenic, mutagenic toxicity, and no reproductive toxicity.

Meloxicam is a nonsteroidal anti-inflammatory analgesic (NSAID) of the enolic acid class, which has anti-inflammatory, analgesic and antipyretic effects. It exerts the above effects by inhibiting the biosynthesis of inflammatory mediators prostaglandins, and selectively inhibits COX-2 more strongly than COX-1, thereby reducing gastrointestinal and renal side effects. Clinical studies have shown that the incidence of gastrointestinal adverse reactions is low when the recommended dose of meloxicam is used.

Not yet clear

It belongs to the macrolide antibiotics, acts on the 50S subunit of bacterial cell ribosomes, inhibits the synthesis of bacterial proteins. It improves the lipophilicity of erythromycin, increases absorption, reduces serum protein binding rate, improves antibacterial activity, and reduces toxicity. It is effective against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, mycoplasma, chlamydia, spirochetes, Legionella, Campylobacter, and amoeba.

This product is a quinolone antibacterial drug. It is a broad-spectrum antibacterial drug. It has obvious antibacterial effects on Gram-positive bacteria including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, and Enterococcus faecalis; it also has good antibacterial effects on Gram-negative bacteria Escherichia coli, Klebsiella, Salmonella, Shigella, Vibrio parahaemolyticus, Proteus, Enterobacter, Pseudomonas, Acinetobacter, Neisseria (Neisseria gonorrhoeae, etc.). This product also has good antibacterial effects on mycoplasma, chlamydia, Legionella, anaerobic bacteria including Bacteroides fragilis and Mycobacterium. The mechanism of action of this product is to inhibit the action of DNA gyrase in the process of bacterial DNA synthesis and play a bactericidal role.